Ruthenium-based complexes have emerged as promising antitumor and antimetastatic
agents during the past decades. However, the limited understanding of the antimetastatic …

Ruthenium (II) arene complexes exhibit promising chemotherapeutic properties. In this
study, the effect of the counter anion in Ru (II) complexes was evaluated by analyzing the …

Due to the side effects of marketed cancer drugs, we designed a series of ruthenium-based
fluorescent anticancer drugs, which was demonstrated to be target specific, highly …

A series of arene ruthenium (II)(Ru) complexes with N-monodentate (AAP) and N, O-and N,
N-bidentate chelating ligands (AAPS, ADABS, AAPPA and P2P) have been synthesized and …

Following promising recent in vitro and in vivo studies of the anticancer efficacies of
heterometallic titanocene–gold chemotherapeutic candidates against renal cancer, we …

Background Platinum-based anticancer drugs have been at the frontline of cancer therapy
for the last 40 years, and are used in more than half of all treatments for different cancer …

New ruthenium (II) arene derivatives (arene= p-cymene, benzene, hexamethylbenzene)
containing β-ketoamine ligands L′(HL′ in general; in detail, HLph, ph=(4 Z)-3-methyl-4 …

More than 10 million death tolls in 2020 were reported as a result of heinous impact of
cancer, making it second most prime cause of death after cardiovascular diseases. In …

Upon exploration of the chemistry of the combination of ruthenium/arene with anthraquinone
alizarin (L), three new complexes with the general formulas [Ru (L) Cl (η6-p …

Cisplatin was the first metal-based therapeutic agent approved for the treatment of human
cancers, but its clinical activity is greatly limited by tumor drug resistance. This work utilized …